AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions.

Saved in:
Bibliographic Details
Title: AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions.
Authors: Swaih AM; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Talbot S; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Savoca A; Clinical Pharmacology and Safety Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Thorpe H; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Flemington V; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Phillips B; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Colclough N; DMPK, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., McCoull W; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Radeva V; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Hargreaves D; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Packer MJ; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Felisberto-Rodrigues C; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Thomson C; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Orme JP; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Deane C; DMPK, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Smith A; DMPK, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Johnström P; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Stockholm 171 76, Sweden., Schou M; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Stockholm 171 76, Sweden., McWilliams L; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Davey P; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Enget M; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., O'Neill D; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Cosulich S; Early Oncology Development, Oncology R&D AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Floc'h N; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK. Electronic address: nicolas.floch@astrazeneca.com.
Source: Cell reports. Medicine [Cell Rep Med] 2025 Sep 16; Vol. 6 (9), pp. 102305. Date of Electronic Publication: 2025 Aug 25.
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3791
DOI:10.1016/j.xcrm.2025.102305